Premature Termination or Suspension Section
A Premature Termination or Suspension section covers the unplanned early-stop pathway: immediate participant considerations, notification, documentation, follow-up, and responsibility allocation. It is distinct from routine planned study closeout.
A Premature Termination or Suspension section explains who acts, who is notified, how reasons are documented, and how participants and records are protected if the trial stops early or is suspended.
Key details
Important caveats
Scope Boundary
Keep this separate from Study Closeout, which covers planned end-of-study activities. Exact notification recipients and timelines depend on who initiates the stop and applicable requirements.
Further guidance
Content
State decision authority, immediate participant-safety and treatment-continuity steps, investigator/sponsor/regulator/ethics notifications as applicable, documentation of reasons, record handling, and required follow-up.
Purpose
Ensure an unexpected halt is managed transparently and safely rather than treated as an ordinary scheduled closeout.
Sources and evidence
Sources are shown with the role they play in this guide. Historical or style-sensitive claims are kept within the evidence boundary described above.
- E6(R3) Good Clinical Practice Guidance for Industry — September 2025 (opens in a new tab)U.S. Food and Drug Administration · Current ICH E6(R3) GCP guidance on investigator oversight, training/delegation, participant withdrawal, investigational-product accountability, site close-out, essential records, and insurance/indemnification
- E6(R3) Good Clinical Practice (GCP) — September 2025 (opens in a new tab)U.S. Food and Drug Administration · Current FDA final-guidance overview for ICH E6(R3), including quality by design, risk-based quality management, technology, proportionality, and clarified sponsor/investigator responsibilities